Literature DB >> 10807063

Fracture risk in patients treated for hyperthyroidism.

P Vestergaard1, L Rejnmark, J Weeke, L Mosekilde.   

Abstract

AIM: To study fracture risk and risk factors for fractures in patients with hyperthyroidism.
DESIGN: Historical follow-up.
MATERIAL AND METHODS: A total of 864 patients with diffuse toxic goiter (ICD 10: E05.0) or toxic nodular goiter (E05.2) were contacted through a self-administered questionnaire. Each respondent was compared to an age: (+/- 5 years) and gender-matched control from a random sample of the background population who responded to the same questionnaire.
RESULTS: Among the patients 621 (72%) responded and of these 617 could be analyzed. Within the first 5 years before the diagnosis, the patients had the same fracture risk as the controls (RR = 1.2, 95% CI; 0.7-2.0). After the diagnosis, fracture risk was elevated among the patients (RR = 1.7, 95% CI: 1.2-2.3), especially in the age group 50 years or older (RR = 2.2, 95% CI: 1.5-3.3). Fracture risk was elevated for fractures of the spine (RR = 8.9, 95% CI: 1.6-48.4), and the forearms (RR = 3.1, 95% CI: 1.6-6.2), but not at other skeletal sites. Treatment with radioactive iodine alone was associated with an increased fracture risk (OR = 2.7, 95% CI: 1.2-6.0), a risk that was not present in patients who, in addition to radioactive iodine, also had received methimazole (RR = 1.5, 95% CI: 0.7-3.2).
CONCLUSIONS: Our study demonstrated an increased fracture risk in hyperthyroidism, a fracture risk that was present with radioactive iodine treatment alone, but not in subjects that had received both radioactive iodine and methimazole or other types of antithyroid therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807063     DOI: 10.1089/thy.2000.10.341

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

1.  Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.

Authors:  Takafumi Majima; Yasato Komatsu; Kentaro Doi; Chieko Takagi; Michika Shigemoto; Atsushi Fukao; Takeshi Morimoto; Jerry Corners; Kazuwa Nakao
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease.

Authors:  T Majima; Y Komatsu; K Doi; C Takagi; M Shigemoto; A Fukao; T Morimoto; J Corners; K Nakao
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

3.  Epidemiology of major osteoporotic fractures: a population-based analysis in Catalonia, Spain.

Authors:  Xavier Surís; Emili Vela; Montserrat Clèries; Maria-Jesús Pueyo-Sánchez; Esteve Llargués; Marta Larrosa
Journal:  Arch Osteoporos       Date:  2022-03-10       Impact factor: 2.617

4.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

5.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

6.  The influence of thyroid dysfunction on bone metabolism.

Authors:  Dominika Tuchendler; Marek Bolanowski
Journal:  Thyroid Res       Date:  2014-12-20

7.  Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.

Authors:  Monica A Ercolano; Monica L Drnovsek; Maria C Silva Croome; Monica Moos; Ana M Fuentes; Fanny Viale; Ulla Feldt-Rasmussen; Alicia T Gauna
Journal:  Thyroid Res       Date:  2013-09-11

Review 8.  Bone disease in thyrotoxicosis.

Authors:  P Amaresh Reddy; C V Harinarayan; Alok Sachan; V Suresh; G Rajagopal
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

9.  Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone.

Authors:  Elżbieta Skowrońska-Jóźwiak; Krzysztof C Lewandowski; Zbigniew Adamczewski; Kinga Krawczyk-Rusiecka; Andrzej Lewiński
Journal:  Int J Endocrinol       Date:  2015-08-23       Impact factor: 3.257

10.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.